1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1111/j.1600-0447.1998.tb05973.x" target="_blank" rel="noreferrer">http://doi.org/10.1111/j.1600-0447.1998.tb05973.x</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management
Publisher
An entity responsible for making the resource available
Acta Psychiatrica Scandinavica, Supplementum
Date
A point or period of time associated with an event in the lifecycle of the resource
1998
Subject
The topic of the resource
Treatment Outcome; Anti-Anxiety Agents; Syndrome; Human; Animal; Anti-Anxiety Agents; Anxiety Disorders/dt [Drug Therapy]; Substance Withdrawal Syndrome/di [Diagnosis]; Substance-Related Disorders/di [Diagnosis]; Anxiety Disorders/px [Psychology]; Benzodiazepine; Benzodiazepine/ae [Adverse Effects]; Benzodiazepine/tu [Therapeutic Use]; Substance Withdrawal Syndrome/rh [Rehabilitation]; Substance-Related Disorders/rh [Rehabilitation]
Creator
An entity primarily responsible for making the resource
Schweizer E; Rickels K
Description
An account of the resource
The treatment of anxiety has evolved through various phases. Currently, there is a growing recognition that anxiety disorders are frequently chronic and/or recurrent. There is also less optimism than a decade ago that benzodiazepines will be replaced by alternative agents that are not active at the benzodiazepine receptor. Consequently, the understanding and management of benzodiazepine dependence and withdrawal continue to be of some clinical importance. This article briefly reviews the withdrawal syndrome and the pharmacological and patient variables that contribute to it. It then summarizes the various approaches to managing benzodiazepine dependence and withdrawal. [References: 39]
1998
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1111/j.1600-0447.1998.tb05973.x" target="_blank" rel="noreferrer">10.1111/j.1600-0447.1998.tb05973.x</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1998
Acta Psychiatrica Scandinavica, Supplementum
Animal
Anti-Anxiety Agents
Anxiety Disorders/dt [Drug Therapy]
Anxiety Disorders/px [Psychology]
Backlog
Benzodiazepine
Benzodiazepine/ae [Adverse Effects]
Benzodiazepine/tu [Therapeutic Use]
Human
Journal Article
Rickels K
Schweizer E
Substance Withdrawal Syndrome/di [Diagnosis]
Substance Withdrawal Syndrome/rh [Rehabilitation]
Substance-Related Disorders/di [Diagnosis]
Substance-Related Disorders/rh [Rehabilitation]
Syndrome
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1007/s00508-006-0611-4" target="_blank" rel="noreferrer">http://doi.org/10.1007/s00508-006-0611-4</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial
Publisher
An entity responsible for making the resource available
Wiener Klinische Wochenschrift
Date
A point or period of time associated with an event in the lifecycle of the resource
2006
Subject
The topic of the resource
Female; Humans; Male; Middle Aged; Treatment Outcome; Anti-Anxiety Agents; Double-Blind Method; Cross-Over Studies; quality of life; Chronic disease; Pain/drug therapy; Pain Measurement/drug effects; Adjuvant; Cannabinoids/administration & dosage; Chemotherapy; Placebo Effect; Tetrahydrocannabinol/administration & dosage/analogs & derivatives
Creator
An entity primarily responsible for making the resource
Pinsger M; Schimetta W; Volc D; Hiermann E; Riederer F; Polz W
Description
An account of the resource
OBJECTIVE: The aim of this study was to investigate the efficacy and efficiency of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain. Of major interest were the evaluation of the influence the treatment had on pain and on quality of life as well as the subjective assessment of positive effects and side effects by the study participants. METHODS: The placebo-controlled double-blinded pilot study was divided into a 14 week cross-over period (two 4 week medication phases plus wash-out phases) followed by a 16 week medication switch period with free choice of the study drugs (drug A and drug B) by the study participants. The principal inclusion criterion was chronic therapy-resistant pain in causal relationship with a pathologic status of the skeletal and locomotor system. The study participants chose the dosage of the study drug themselves (between 1 und 4 capsules/day, in the case of nabilone this corresponds to (1/4)-1 mg/day). Pain intensity was assessed by a visual analogue scale (VAS), quality of life by the Mezzich and Cohen QOL-score. RESULTS: Altogether, 30 patients were included and analyzed. From the results, it is obvious that throughout the cross-over periods the nabilone treatment was superior (medians [25%-; 75%-percentiles]: nabilone/placebo): decrease of the average spinal pain intensity within the last 4 weeks (DeltaVAS) 0.9 [0.0; 2.0] / 0.5 [0.0; 1.7], decrease of the current spinal pain intensity (DeltaVAS) 0.6 [0.0; 2.5] / 0.0 [-1.0, 1.0] (p = .006), decrease of the average headache intensity within the last 4 weeks (DeltaVAS) 1.0 [-1.0; 2.4] / 0.2 [-0.9; 1.0], increase of the number of days without headache within the last 4 weeks 2.0 [0.0; 6.5] / 0.0 [-5.0; 4.0], increase of the quality of life (DeltaQOL-Score) 5.0 [0.8; 10.8] / 2.0 [-2.3; 8.0]. In the medication switch period, the number of study participants who favoured nabilone (nabilone intake > or =85% of all medication days) was more than 4 times higher than those who favoured placebo. The number of days with nabilone intake was clearly higher than the number with placebo intake (medians: 89% vs. 11% of all medication days, p = .003). CONCLUSION: In summary, the study results allow the conclusion that a majority of patients with chronic pain classify nabilone intake in addition to the standard treatment as a measure with a positive individual benefit-riskratio. Thus, this kind of treatment may be an interesting and attractive enrichment of analgetic therapy concepts.
2006
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/s00508-006-0611-4" target="_blank" rel="noreferrer">10.1007/s00508-006-0611-4</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2006
Adjuvant
Anti-Anxiety Agents
Backlog
Cannabinoids/administration & dosage
Chemotherapy
Chronic Disease
Cross-Over Studies
Double-Blind Method
Female
Hiermann E
Humans
Journal Article
Male
Middle Aged
Pain Measurement/drug effects
Pain/drug Therapy
Pinsger M
Placebo Effect
Polz W
Quality Of Life
Riederer F
Schimetta W
Tetrahydrocannabinol/administration & dosage/analogs & derivatives
Treatment Outcome
Volc D
Wiener Klinische Wochenschrift